Cargando…
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial
Objective To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Design Randomised placebo controlled double blind trial. Setting 13 hospitals in Italy Participants 508 patients with mil...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845783/ https://www.ncbi.nlm.nih.gov/pubmed/20339154 http://dx.doi.org/10.1136/bmj.c1197 |
_version_ | 1782179437151780864 |
---|---|
author | Mancia, Giuseppe Parati, Gianfranco Revera, Miriam Bilo, Grzegorz Giuliano, Andrea Veglia, Fabrizio Crepaldi, Gaetano Zanchetti, Alberto |
author_facet | Mancia, Giuseppe Parati, Gianfranco Revera, Miriam Bilo, Grzegorz Giuliano, Andrea Veglia, Fabrizio Crepaldi, Gaetano Zanchetti, Alberto |
author_sort | Mancia, Giuseppe |
collection | PubMed |
description | Objective To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Design Randomised placebo controlled double blind trial. Setting 13 hospitals in Italy Participants 508 patients with mild hypertension and hypercholesterolaemia, aged 45 to 70 years. Intervention Participants were randomised to antihypertensive treatment (hydrochlorothiazide 25 mg once daily or fosinopril 20 mg once daily) with or without the addition of a statin (pravastatin 40 mg once daily). Main outcome measures Clinic and ambulatory blood pressure measured every year throughout an average 2.6 year treatment period. Results Both the group receiving antihypertensive treatment without pravastatin (n=254) (with little change in total cholesterol) and the group receiving antihypertensive treatment with pravastatin (n=253) (with marked and sustained reduction in total cholesterol and low density lipoprotein cholesterol) had a clear cut sustained reduction in clinic measured systolic and diastolic blood pressure as well as in 24 hour, and day and night, systolic and diastolic blood pressure. Pravastatin performed slightly worse than placebo, and between group differences did not exceed 1.9 (95% confidence interval −0.6 to 4.3, P=0.13) mm Hg throughout the treatment period. This was also the case when participants who remained on monotherapy with hydrochlorothiazide or fosinopril throughout the study were considered separately. Conclusions Administration of a statin in hypertensive patients in whom blood pressure is effectively reduced by concomitant antihypertensive treatment does not have an additional blood pressure lowering effect. Trial registration BRISQUI_*IV_2004_001 (registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali—National Monitoring Centre on Clinical Research with Medicines). |
format | Text |
id | pubmed-2845783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-28457832010-04-26 Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial Mancia, Giuseppe Parati, Gianfranco Revera, Miriam Bilo, Grzegorz Giuliano, Andrea Veglia, Fabrizio Crepaldi, Gaetano Zanchetti, Alberto BMJ Research Objective To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Design Randomised placebo controlled double blind trial. Setting 13 hospitals in Italy Participants 508 patients with mild hypertension and hypercholesterolaemia, aged 45 to 70 years. Intervention Participants were randomised to antihypertensive treatment (hydrochlorothiazide 25 mg once daily or fosinopril 20 mg once daily) with or without the addition of a statin (pravastatin 40 mg once daily). Main outcome measures Clinic and ambulatory blood pressure measured every year throughout an average 2.6 year treatment period. Results Both the group receiving antihypertensive treatment without pravastatin (n=254) (with little change in total cholesterol) and the group receiving antihypertensive treatment with pravastatin (n=253) (with marked and sustained reduction in total cholesterol and low density lipoprotein cholesterol) had a clear cut sustained reduction in clinic measured systolic and diastolic blood pressure as well as in 24 hour, and day and night, systolic and diastolic blood pressure. Pravastatin performed slightly worse than placebo, and between group differences did not exceed 1.9 (95% confidence interval −0.6 to 4.3, P=0.13) mm Hg throughout the treatment period. This was also the case when participants who remained on monotherapy with hydrochlorothiazide or fosinopril throughout the study were considered separately. Conclusions Administration of a statin in hypertensive patients in whom blood pressure is effectively reduced by concomitant antihypertensive treatment does not have an additional blood pressure lowering effect. Trial registration BRISQUI_*IV_2004_001 (registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali—National Monitoring Centre on Clinical Research with Medicines). BMJ Publishing Group Ltd. 2010-03-25 /pmc/articles/PMC2845783/ /pubmed/20339154 http://dx.doi.org/10.1136/bmj.c1197 Text en © Mancia et al 2010 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Research Mancia, Giuseppe Parati, Gianfranco Revera, Miriam Bilo, Grzegorz Giuliano, Andrea Veglia, Fabrizio Crepaldi, Gaetano Zanchetti, Alberto Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title_full | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title_fullStr | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title_full_unstemmed | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title_short | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial |
title_sort | statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from phyllis randomised double blind trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845783/ https://www.ncbi.nlm.nih.gov/pubmed/20339154 http://dx.doi.org/10.1136/bmj.c1197 |
work_keys_str_mv | AT manciagiuseppe statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT paratigianfranco statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT reveramiriam statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT bilogrzegorz statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT giulianoandrea statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT vegliafabrizio statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT crepaldigaetano statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial AT zanchettialberto statinsantihypertensivetreatmentandbloodpressurecontrolinclinicandover24hoursevidencefromphyllisrandomiseddoubleblindtrial |